A Prospective study was done about incidence and treatment of hemodynamically significant' patent ductus arteriosus in premature infants admitted to neonatal intensive care unit of Ewha University Hospital from Feb. 1984 for one year. The results were as follows; 1) Among 46 infants with birth weight less than 2,000gm and gestational period 36 wks, 15(32.6%) developed a hemodynamically significant PDA. 2) The incidence of respiratory distress syndrome was six times higher in PDA group than that of non-PDA group(73.3% vs 12.9%). 3) The need for ventilatory assistance was five times higher in PDA group than that of non-PDA group(80% vs 16.1%). 4) The mortality rate was 40% in PDA group, 15% in non-PDA group. 5) The ratio of left atrium to aorta(LA/AO) in M-mode echocardiography was significantly higher in PDA group than that of non-PDA group(1.21+/-0.18 vs 0.93+/-0.23). 6) Indomethacin treated with usual medical therapy resulted in ductal closure in 80%, 20% with usual medical therapy only. 7) The mean LA/AO ratio was significantly decreased after indomethacin treatment(1.15+/-0.13 vs 1.21+/-0.18). 8) The change of the value of plasma sodium and potassium was not significant during indomethacin therapy, whereas BUN, creatinine value was increased during treatment, but that was reversible.
Birth Weight ; Creatinine ; Ductus Arteriosus, Patent* ; Echocardiography ; Heart Atria ; Humans ; Incidence ; Indomethacin ; Infant ; Infant, Newborn ; Infant, Premature* ; Intensive Care, Neonatal ; Mortality ; Plasma ; Potassium ; Prospective Studies ; Sodium

Cyclopia is rare congenital craniofacial anomaly, in which the eyes are fused together and located in a single orbit. It is consistently associated with severe holoprosencephaly, which is the failure of cleavage of the prosencephalon with a deficit in the midline facial development. chromosomal study revealed 47, X( ), +13 (Patau syndrome).
Holoprosencephaly ; Orbit ; Prosencephalon ; Trisomy*

No abstract available.
Humans

BACKGROUND: Nitric Oxide (NO) has been discovered to be an important endothelium-derived relaxing factor. The exogenous inhaled NO may diffuse from the alveoli to pulmonary vascular smooth muscle and produce pulmonary vasodilation, but any NO that diffuses into blood will be inactivated before it can produce systemic effects. To examine the effects of NO on pulmonary and systemic hemodynamics, NO was inhaled by experimental dogs in an attempt to reduce the increase in pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) induced by hypoxia in dogs. METHODS: Eight mongrel dogs were studied while inhaling 1)50% O2 (baseline), 2)12% O2 in N2 (hypoxia), 3)followed by the same hypoxic gas mixture of O2 and N2 containing 20, 40 and 80 ppm of NO, respectively. RESULTS: Breathing at FIO2 0.12 nearly doubled the pulmonary vascular resistance from 173 56dyn sec cm-5 to 407 139dyn sec cm-5 and significantly increased the mean pulmonary artery pressure from 16 3mmHg to 22 4mmHg. After adding 20~80 ppm NO to the inspired gas while maintaining the FIO2 at 0.12, the mean pulmonary artery pressure decreased (p<0.05) to the level when breathing oxygen at FIO2 0.5 while the PaO2 and PaCO2 were unchanged. The pulmonary vascular resistance decreased significantly and the right ventricular stroke work index returned to a level similar to breathing at FIO2 0.5 by addition of NO into the breathing circuit. Pulmonary hypertension resumed within 3~5 minutes of ceasing NO inhalation. In none of our studies did inhaling NO produce systemic hypotension and elevate methemoglobin levels. CONCLUSIONS: Inhalation of 20~80 ppm NO selectively induced pulmonary vasodilation and reversed hypoxic pulmonary vasoconstriction without causing systemic vasodilation and bronchodilation. Methemoglobin and NO2 were within normal limit during the study.
Animals ; Anoxia ; Dogs ; Endothelium-Dependent Relaxing Factors ; Hemodynamics* ; Hypertension, Pulmonary ; Hypotension ; Inhalation* ; Methemoglobin ; Muscle, Smooth, Vascular ; Nitric Oxide* ; Oxygen ; Pulmonary Artery ; Respiration ; Stroke ; Vascular Resistance ; Vasoconstriction* ; Vasodilation

No abstract available.
Child* ; Humans ; Lymphangioma*

Clinical studies were performed that the patient with angina pectoris having no responses to Ca++ antagonist and beta-blocker had been taken nicorandil 5mg bid daily with, beta-blokade and Ca++ antagonists for 3 weeks. The results after the use of nicorandil were as follows; 1) The clinical symptoms after the use of nicorandil were improved in 20(80%) of 25 patients, specially marked improved in 16 of 25 patients. There was no significant changes of BP and heart rate after the use of nicorandil. 2) The results of CBC, urinalysis, serum chemistry exa. and chest P-A were within normal range before and after the use of nicorandil. 3) After the use of nicorandil, ST segments depressed in 13 of 25 patients before use of nicorandil was elevated in 8(61.6%) of 13 cases after the use of that. QT interval, P-R interval and T wave in 25 cases were within normal range before and after the use of that. The M mode echocardiography showed the decreased movement of ventricular septum in 19 of 25 patients before the use of Nicorandil, and there was no changes after the use of that. 4) The adverse effects after the use of nicorandil to 25 patients were as follows: headache in 3(12%), nausea and vomiting 2(8%), palpitation 1(4%), upper abdominal discomfort 1(4%), and facial flushing 1(4%).
Angina Pectoris* ; Chemistry ; Echocardiography ; Flushing ; Headache ; Heart Rate ; Humans ; Nausea ; Nicorandil* ; Reference Values ; Thorax ; Urinalysis ; Ventricular Septum ; Vomiting

No abstract available.
Asthma* ; Child* ; Humans ; Lymphadenitis*

AO bilirubinometer is a direct reading spectrophotometer specifically designed to measure total bilirubin using sera from newborn infantsl A study was performed to compare the bilirubin values obtained using the AO bilirubibometer and modified Diazo method(Rappaport method). The results were as follows : 1. The average percentage of recovery of AO bilirubinometer was 98.7%, while modified Diazo method was represented as 95.3%. 2. In comparison of two bilirubin techniques, the regression is linear, expressed by Y=1.16X-2.42, where values obtained as the bilirubinometer was on X axis and those from the modified Diazo mt\ethod on Y axis. The correlation coefficient was 0.95. 3. The variability of bilirubin values by cuvette was negligible, average percentage of variation coefficient being 0.1%. 4. The variability of bilirubin values by examiner was also negligible, the evarage percentage of bilirubin variation coefficient being 0.67%.
Axis, Cervical Vertebra ; Bilirubin ; Humans ; Hyperbilirubinemia, Neonatal* ; Infant, Newborn

No abstract available.
Thanatophoric Dysplasia*